Ships within 24 hours on business days · +10% with Bank Pay

Thymalin

Shop

Thymalin · Research brief

Thymalin vs Thymogen, Epitalon and TB-500 Compared

42 WORDS

Short answer

In thymalin vs thymogen, the practical difference is compositional: Thymalin is a multi-component polypeptide fraction isolated from calf thymus tissue, while Thymogen is a single synthetic dipeptide, L-glutamyl-L-tryptophan, built as a defined-sequence stand-in for the smallest active unit attributed to that fraction.

In thymalin vs thymogen, the practical difference is compositional: Thymalin is a multi-component polypeptide fraction isolated from calf thymus tissue, while Thymogen is a single synthetic dipeptide, L-glutamyl-L-tryptophan, built as a defined-sequence stand-in for the smallest active unit attributed to that fraction. Epitalon is a four-residue synthetic peptide modelled on a pineal gland extract rather than a thymic one, and TB-500 sits in an entirely different family, the beta-thymosins, whose defining biochemical property is actin binding rather than immune signalling. This page places the four compounds side by side by origin, molecular class and the research endpoints each has actually been studied against, and it states plainly where the published record is thin or confined to a single research tradition. Real Peptides supplies Thymalin and TB-500 as research-use-only compounds, with independent third-party certificates of analysis published for every batch at /coas/.

What is the core difference between Thymalin and Thymogen?

Thymalin is an extract and Thymogen is a molecule. That single distinction drives almost every other difference between them, including how each is characterised analytically, how reproducible a given batch can be, and what kind of experiment each one suits.

Thymalin is described in the literature as a low-molecular-weight polypeptide complex obtained from the thymus of calves. It is not one sequence. It is a fraction, a population of related peptides recovered together by extraction and separation steps, and its identity is therefore defined by the process that produced it and by the analytical fingerprint of the finished material rather than by a single mass or a single amino acid string. Research groups working in this tradition have historically characterised such fractions by molecular weight range and by functional assay, not by one sharp peak on a mass spectrum.

Thymogen is the opposite case. It is L-glutamyl-L-tryptophan, a dipeptide of two residues, synthesised rather than extracted. Its molecular mass is fixed, its sequence is unambiguous, and a batch can be verified against reference standards in a way that a tissue fraction cannot. The rationale published for short peptides of this kind, set out in the monograph Peptides and Ageing in Neuro Endocrinology Letters in 2002, is that the biological signal carried by a complex tissue extract can in principle be reduced to very short defined sequences, which are then easier to synthesise, characterise and study.

For a laboratory choosing between the two, the choice is usually methodological. A defined dipeptide is the better instrument when the question concerns a specific sequence, a receptor interaction or a gene expression readout that must be attributable to one molecule. An extract fraction is relevant when the research question concerns the historical preparation itself, since much of the older immunology literature in this area was generated with the fraction and not with the dipeptide. Results obtained with one should not be assumed to transfer to the other, and the published work does not establish equivalence between them.

What are the origins and molecular classes of these four peptides?

The four compounds come from three distinct research lineages: thymic extracts and their synthetic analogues, pineal extracts and their synthetic analogues, and the beta-thymosin actin-binding proteins. Setting origin next to molecular class is the fastest way to see why their published endpoints diverge.

Compound Origin Molecular class Sequence definition Research tradition
Thymalin Calf thymus tissue extract Multi-component polypeptide fraction No single sequence; defined by fraction and analytical profile Soviet and Russian peptide immunology and gerontology
Thymogen Chemical synthesis Dipeptide L-glutamyl-L-tryptophan, two residues Synthetic short-peptide derivative of the thymic line
Epitalon Chemical synthesis Tetrapeptide Ala-Glu-Asp-Gly, four residues Synthetic analogue modelled on pineal extract research
TB-500 Chemical synthesis Beta-thymosin family peptide or fragment thereof Catalog items vary; commonly the full 43-residue thymosin beta 4 sequence or a fragment containing the actin-binding motif International cell biology and regenerative medicine

Two points in that table matter more than the rest. First, only one of the four, Thymalin, is an extract. The other three are synthetic and can be verified against a stated molecular formula and mass. Second, TB-500 is the only one of the four whose parent molecule is a well-characterised intracellular protein with a defined biochemical function in cells across many species. Thymosin beta 4 is an actin-sequestering peptide, abundant in many cell types, and its biology was worked out in mainstream cell biology journals rather than within a single national research programme.

The naming of TB-500 deserves its own caution. The designation is used in research catalogs for more than one material. Some items correspond to the complete thymosin beta 4 sequence, others to a shorter synthetic fragment containing the actin-binding region. These are not interchangeable in an assay, and a published result obtained with full-length thymosin beta 4 cannot be assumed to describe a fragment. Verification of the molecular identity stated on the certificate of analysis, rather than reliance on the catalog name alone, is the only reliable way to know which material is in hand. The Real Peptides TB-500 compound page and the Thymalin compound page set out what each listed item is.

How does Thymalin work in published research models?

The mechanism attributed to Thymalin in the published literature is immune modulation at the level of thymus-dependent cell populations, with downstream effects on endocrine and haemostatic indices reported in the same body of work. The proposal is regulatory rather than replacement: the fraction is described as restoring a signalling input that declines as the thymus involutes with age, not as supplying a hormone in deficit.

The experimental record that supports this framing sits largely in the Russian gerontology and peptide regulation literature. The monograph Peptides and Ageing, published in Neuro Endocrinology Letters in 2002, collects a large volume of that work in one place, covering thymic and pineal peptide preparations, cell culture findings, animal lifespan experiments and human observational series. It describes effects on lymphocyte subsets, on indices of cellular immunity and on markers of biological age, and it frames short peptides as regulators of gene expression. As a source it is a review and monograph rather than a single controlled experiment, so it reports the tradition's conclusions rather than independently testing them.

The most frequently cited human work involving this compound is Peptides of pineal gland and thymus prolong human life, also in Neuro Endocrinology Letters, 2003. That report followed older adult participants over a period of several years, with arms receiving thymic peptide preparation, pineal peptide preparation, both, or neither, and it reported improvements in immune and endocrine indices in the peptide arms along with lower mortality across the observation period. Research suggests this is the strongest human signal available for the compound, and it is also the clearest illustration of the evidence problem: the work comes from the group that developed the preparations, the observation period and cohort structure limit what can be concluded, and independent replication outside that tradition is not available in the indexed literature.

What the literature does not provide is a resolved molecular mechanism. There is no single receptor, no single transduction pathway and no consensus structural model for a fraction that contains multiple peptides. Studies report outcomes at the level of cell populations and clinical indices, which is a legitimate level of description but one that leaves mechanism open.

How does Thymogen differ in mechanism and studied endpoints?

Thymogen was developed to answer precisely the mechanistic gap left by the extract, by reducing activity to a two-residue sequence that can be synthesised, characterised and studied as one molecule. Its studied endpoints overlap with the thymic extract literature, concentrating on immune cell populations and on resistance measures in infection and stress models.

The case for very short peptides as regulators is laid out in Peptides and Ageing, which treats dipeptides and tripeptides as sequence-specific signals capable of interacting with DNA and chromatin and thereby modulating transcription. On that model, a glutamyl-tryptophan dipeptide is not a nutrient or a structural fragment but an information-carrying ligand whose two side chains determine which sites it engages. The model is coherent and has generated a large number of publications within the tradition, but it is not broadly corroborated by independent structural biology, and the specific binding claims for individual short peptides remain contested outside that literature.

In comparative terms the dipeptide has several practical advantages for a laboratory. Synthesis is straightforward, batch-to-batch identity can be confirmed by standard analytical methods, solubility behaviour is predictable for a small polar peptide, and attribution of any observed effect to a defined chemical entity is possible. The extract offers none of those. Against that, the dipeptide carries a much smaller body of published work than thymosin beta 4 does, and the majority of it is in Russian-language journals or in review form, which limits what an independent group can verify before designing a study.

The honest summary is that the dipeptide and the extract are studied for similar immune endpoints by overlapping research groups, that the dipeptide is the cleaner experimental object, and that the published literature does not demonstrate that one reproduces the other. Treating them as different compounds with a shared research origin is more defensible than treating them as a preparation and its purified active ingredient.

What does the literature report when comparing Thymalin and Epitalon?

In thymalin vs epitalon the organ of origin is the dividing line: one preparation derives from thymus research and targets immune endpoints, while the other derives from pineal gland research and targets circadian, neuroendocrine and cellular senescence endpoints. They are frequently discussed together because they were developed in the same programme and were studied in the same human series, not because they share a mechanism.

Epitalon is the tetrapeptide Ala-Glu-Asp-Gly, a synthetic sequence modelled on the pineal extract used in the earlier work. The endpoint that made it widely known is telomere biology. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells, published in the Bulletin of Experimental Biology and Medicine in 2003, reported induction of telomerase activity and telomere lengthening in cultured human fibroblasts exposed to the peptide. Studies report this as a cell culture finding in a somatic cell line, which is an important limit: telomerase induction in culture does not establish any organism-level outcome, and the result has not been widely replicated in independent laboratories.

The second strand of the comparison is the human series already noted. Peptides of pineal gland and thymus prolong human life examined both preparations in older adults, separately and in combination, and reported that the combination arm performed differently from either single-peptide arm on the indices tracked. That design is the main published basis for the idea that the two compounds act on different systems and might be complementary. It is also, by itself, insufficient to establish that claim, for the same reasons that apply to the rest of the series: single-group authorship, limited independent verification, and endpoints measured as composite indices rather than hard pre-registered outcomes.

For experimental design purposes, the distinction is usable. A research question about lymphocyte subsets, thymic involution or immune competence points toward the thymic preparation. A question about telomerase activity, melatonin rhythm, pineal function or replicative senescence points toward the tetrapeptide. Expecting either to substitute for the other is not supported by anything in the published record.

How does TB-500 differ from Thymalin?

In thymalin vs tb500 the difference is categorical rather than one of degree. The thymic preparation is a tissue-derived mixture studied for immune and ageing endpoints, while TB-500 is a defined synthetic peptide from the beta-thymosin family whose characterised biochemical function is binding monomeric actin and influencing cytoskeletal dynamics, cell migration and angiogenesis.

Thymosin beta 4, the parent molecule, is one of the most abundant intracellular peptides in many mammalian cell types. Its sequestration of G-actin gives it a direct role in how cells remodel their cytoskeleton, which in turn connects it to migration, wound closure and vascular sprouting. That mechanism is not inferred from outcome studies; it is a biochemical property measured directly in vitro, and it is the reason the compound entered mainstream regenerative biology rather than remaining within a single national research programme.

Two papers in Nature anchor the cardiac literature. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair, published in 2004, reported that the peptide promoted migration and survival of cardiac cells and improved functional outcomes in a mouse coronary artery ligation model, with integrin-linked kinase and Akt signalling implicated as the pathway. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization, published in 2007, reported mobilisation of epicardium-derived progenitor cells and new vessel formation in adult mouse heart. Both are animal and cell studies. Neither establishes a human outcome, and the field's later history shows how difficult translation from these models has proved.

The practical consequence for a comparison page is that the two compounds answer different questions and have incompatible readouts. A study of the thymic preparation measures immune cell populations, cytokine profiles or composite ageing indices. A study of the beta-thymosin peptide measures actin polymerisation kinetics, scratch assay closure, endothelial tube formation, progenitor marker expression or infarct size in an animal model. There is no published head-to-head experiment in which both compounds are tested on the same endpoint, so any claim that one outperforms the other on a shared measure has no source behind it.

Which research endpoints has each compound actually been studied against?

Each compound has a distinct endpoint profile, and the table below reflects only endpoints that appear in the published literature discussed on this page rather than claims circulating informally. This is the comparison most researchers are looking for when they search these compounds against one another.

Compound Principal studied endpoints Model types in the cited literature Strength of the indexed evidence
Thymalin Lymphocyte subsets, cellular immunity indices, composite ageing and mortality indices Human observational series, animal work, cell assays within one research tradition Limited; largely single-programme, review-heavy, little independent replication
Thymogen Immune cell population measures, resistance and stress models, transcriptional regulation proposals Animal and cell models, mostly within the same tradition Limited; smaller indexed footprint than the extract, much of it in review form
Epitalon Telomerase activity, telomere length in culture, neuroendocrine and circadian measures, ageing indices Human somatic cell culture, rodent studies, human observational series Limited; one widely cited culture result, sparse independent replication
TB-500 Actin binding, cell migration, angiogenesis, cardiac cell survival, progenitor mobilisation, tissue repair models In vitro biochemistry, cell assays, mouse cardiac injury models Stronger mechanistically; published in general-audience journals, but animal-stage for outcomes

Reading across the rows, the asymmetry is clear. The beta-thymosin peptide has the best-characterised molecular mechanism and the broadest international literature, yet its outcome data remain preclinical. The thymic and pineal compounds have human observational data, which sounds stronger, but that data comes from a narrow source base and uses composite indices that are difficult for an outside group to reproduce. Neither profile is a substitute for the other, and neither supports a therapeutic claim.

The limits worth naming explicitly are these: cell culture telomerase induction is not organism-level ageing data; rodent infarct models are not human cardiac outcomes; composite biological age indices are constructs, not direct measures; and review monographs summarising a programme's own output cannot serve as independent confirmation of that output. These caveats apply to every comparison statement on this page.

How do the evidence bases compare in quality and accessibility?

The four compounds differ as much in the shape of their evidence as in their chemistry, and for research planning that difference is often decisive. Accessibility of primary sources, language of publication, independence of replication and journal reach all vary across the set.

Thymosin beta 4 research is the most accessible. Primary papers are in English, indexed, and published across cell biology, cardiology and ophthalmology literature, with the two Nature reports cited above among the most visible. Methods sections are detailed enough for an independent laboratory to attempt replication, and reagents are standard. That does not make the findings definitive, but it does mean a research group can read the primary literature, see the assays and design a comparable experiment.

The thymic and pineal peptide literature is harder to work with. A large share of the primary experimental reports are in Russian-language journals that are not fully indexed or translated, and much of what is accessible in English takes the form of reviews and monographs that summarise rather than report. Peptides and Ageing is the clearest example, valuable as a map of the programme but not as an independent test of it. Where primary English-language reports exist, such as the telomerase culture study in the Bulletin of Experimental Biology and Medicine and the human series in Neuro Endocrinology Letters, they are short papers with limited methodological detail by current standards.

Independent replication is the sharpest divider. Beta-thymosin findings have been examined by multiple unaffiliated groups, with results that are mixed in places, which is itself informative. The thymic, dipeptide and tetrapeptide findings have largely not been reproduced outside the originating programme, so the literature is internally consistent but externally untested. Research suggests this pattern should be read as unresolved rather than as refuted. Absence of independent replication is not evidence against a compound, but it does cap how much weight a conclusion can carry.

For a laboratory setting priorities, the implication is that experimental design for the thymic and pineal compounds carries more burden. Baselines, controls and endpoint definitions cannot simply be lifted from the prior literature, because that literature often does not specify them at the level a modern protocol requires.

Do these peptides appear together in published research designs?

Yes, but only in one pairing with a published rationale, and that rationale is narrower than it is often represented. The thymic and pineal preparations were studied in combination in the human observational series described above, which is the single published design in which two of these four compounds were examined together in the same cohort.

Peptides of pineal gland and thymus prolong human life included arms receiving each preparation alone and an arm receiving both, and reported that the combined arm differed from the single-compound arms on the indices followed. The stated logic was that the two preparations act on different regulatory systems, thymic and pineal, and that restoring input to both might produce effects that neither produces alone. That logic is plausible on its face and it is the origin of the frequent pairing of these two names in discussion. It remains a single series from a single programme, and no independent group has published a comparable combined design.

No published study combines the beta-thymosin peptide with any of the other three. The compounds come from different literatures, are studied on different endpoints and would require a shared readout for a combination design to mean anything. Claims about synergy between TB-500 and thymic or pineal peptides have no published source, and this page does not make any.

For researchers designing combination work, the relevant methodological point is interpretability. Adding a second compound to an experimental arm multiplies the comparisons needed to attribute any observed effect, and with compounds whose single-agent profiles are themselves not well replicated, combination arms are difficult to interpret in isolation. Factorial designs with single-agent arms, such as the one used in the 2003 series, are the minimum structure that allows any attribution at all. Anything less yields a result that cannot be assigned to either compound.

How should a laboratory verify identity before procurement?

Identity verification should happen before an order is placed, not after the material arrives, and the checks differ depending on whether the compound is a defined synthetic sequence or an extract fraction. This is the single most practical difference between the four compounds discussed here.

For the three synthetic compounds, the dipeptide, the tetrapeptide and the beta-thymosin peptide, verification is straightforward in principle. Each has a stated amino acid sequence, a calculated molecular formula and a molecular mass that an analytical certificate should confirm. Checking the stated CAS number and the molecular mass on the certificate of analysis against the expected values for the sequence is a basic step that catches naming errors and mismatched materials. The TB-500 designation in particular is applied to more than one material across the research market, so confirming whether a listed item corresponds to the full-length sequence or to a shorter fragment matters before any assay is planned.

For the thymic fraction, the verification question is different because there is no single mass to confirm. What a certificate can show for an extract is the analytical profile of the lot, its identity testing and the testing performed by an independent laboratory. Real Peptides publishes independent third-party certificates of analysis for every batch at /coas/, which is where lot documentation for catalog items including Thymalin and TB-500 can be reviewed. The full catalog is listed at /shop/, and shipping origin information is published at /location/.

Documentation practice inside the laboratory matters as much as supplier documentation. Recording the lot number against every experiment, retaining the certificate with the experimental record, and noting the exact compound designation used in the study all protect against the most common source of irreproducibility in peptide research, which is uncertainty about what was actually in the vial. Where a published result is being replicated, matching the material description in the source paper as closely as the record permits is part of the design, and for older papers in this field that description is often incomplete, which should be noted as a limitation in the write-up.

Every compound named on this page is supplied for laboratory research use only. Real Peptides does not provide preparation or use guidance for any catalog item, because these are research-use-only materials and not products for human use.

How is concentration expressed for these compounds in laboratory work?

The arithmetic is simple. A stock concentration in mg/mL is the mass of peptide in the vial divided by the volume of solvent in which it is held. For the three synthetic compounds here, molar concentration is calculable directly from the stated sequence mass, which is one more reason defined peptides are easier experimental objects than fractions. For an extract with no single molecular mass, mass per volume is the only meaningful expression, and molar concentration is not defined.

Reporting conventions follow from that. A paper using a defined peptide should state molar concentration, since it permits comparison across laboratories regardless of what mass of material was weighed. A paper using a fraction can only state mass per volume, which makes cross-laboratory comparison dependent on the fraction being equivalent between batches, an assumption that is rarely tested. When reading the older literature on thymic preparations, this is a frequent source of ambiguity, and it is worth checking what units a source actually reported before attempting to match them.

Real Peptides does not publish preparation instructions, handling procedures or any guidance on use for catalog compounds. What is published is compound identity information on the Thymalin and TB-500 compound pages and lot certificates of analysis at /coas/. Decisions about experimental parameters belong to the investigating laboratory and its own oversight, and no part of this page should be read as guidance toward any use in humans.

What are the main limits of this comparison?

The largest limit is that no published study has tested any two of these four compounds against each other on a common endpoint, so every comparison here is indirect. The table rows sit beside one another because they describe the same categories, not because the underlying experiments were run under comparable conditions.

Three further limits apply across the page. First, evidence depth is unequal by a wide margin, with beta-thymosin biology supported by mechanistic work in widely read journals while the thymic and pineal compounds rest on a narrower and largely untranslated base. Comparing a compound with twenty independent laboratories behind it to one with a single programme behind it will always flatter the former, and that is a feature of the publishing record rather than a verdict on the compounds. Second, model type varies from cell culture to rodent injury models to human observational series, and these are not rungs on a single ladder. A human observational index and a mouse infarct measurement answer different questions and cannot be ranked against each other directly. Third, several of the most cited results are now more than two decades old, and standards for reporting, statistical analysis and material characterisation have changed substantially since.

What this page can support is a description of what each compound is, where it came from, which endpoints the literature has examined and how strong that literature is. What it cannot support is a ranking, a recommendation, or any statement about outcomes in humans. Research suggests each of these four compounds remains an open question in its own right, and the most useful stance for a laboratory is to treat the published work as a starting point for design rather than as a settled conclusion.

All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.

References

  • Peptides and Ageing. Neuro Endocrinology Letters. 2002. PMID: 12374906
  • Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. 2003. PMID: 14523363
  • Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003. PMID: 12937682
  • Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004. PMID: 15565145
  • Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007. PMID: 17108969

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

No. Thymalin is a multi-component polypeptide fraction extracted from calf thymus, while Thymogen is a synthetic dipeptide, L-glutamyl-L-tryptophan. The dipeptide was developed as a defined-sequence derivative of that research line, but the published literature does not establish that it reproduces the activity of the full fraction, so the two are treated as separate compounds.
Both sit within the same research programme and face the same evidence limits. Epitalon has one widely cited cell culture report of telomerase induction in human somatic cells, while Thymalin features in a human observational series over several years. Neither has substantial independent replication outside the originating tradition, so neither can be called better established.
Mainly by name. TB-500 relates to thymosin beta 4, which was originally isolated from thymus tissue, so searches group it with thymic peptides. Mechanistically it belongs to the beta-thymosin actin-binding family and is studied for cell migration, angiogenesis and tissue repair endpoints rather than immune cell population measures.
No published study tests these two compounds against one another on a shared endpoint. Their research literatures use incompatible readouts, with one measuring immune and composite ageing indices and the other measuring actin dynamics, cell migration and cardiac injury model outcomes. Any direct performance comparison between them lacks a published source.
Real Peptides does not provide preparation or use guidance for any catalog item because these are research-use-only compounds. What is published is compound identity information and independent third-party certificates of analysis for every batch. Concentration in laboratory work is expressed as milligrams per millilitre for stock and micrograms per assay for working quantities.
The designation is applied to more than one material. Some listings correspond to the full 43-residue thymosin beta 4 sequence and others to a shorter synthetic fragment containing the actin-binding motif. Checking the stated molecular mass and CAS number on the certificate of analysis before procurement is the only reliable way to confirm which material a listing describes.
Yes. A human observational series published in Neuro Endocrinology Letters in 2003 included arms receiving each preparation alone and an arm receiving both, and reported differences between the combined arm and the single-compound arms. It remains a single series from one research programme, with no independent group publishing a comparable combined design.
Thymosin beta 4 has the clearest characterised mechanism, since actin sequestration is measured directly in vitro rather than inferred from outcomes. Two Nature reports describe cardiac cell migration, survival and epicardial progenitor mobilisation in mouse models. These findings remain preclinical and do not establish human outcomes for any related compound.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now